Objectives and mechanism of iron chelation therapy

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 124-135

  Hershko, Chaim ^a,b   Link, Gabriela ^a   Konijn, Abraham M ^a   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Deferiprone; Deferoxamine; ICL670; Iron chelation; NTBI; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; IRON CHELATING AGENT;

BLOOD TRANSFUSION; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONFERENCE PAPER; DISTRIBUTION VOLUME; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; HEART DISEASE; HEART PROTECTION; HUMAN; IRON CHELATION; IRON OVERLOAD; MONOTHERAPY; MORTALITY; PATIENT COMPLIANCE; THALASSEMIA; THALASSEMIA MAJOR; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 29744458330     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.015     Document Type: Conference Paper

References (38)

1. ANDREWS, N.C. 2002. A genetic view of iron homeostasis. Semin. Hematol. 39: 227-234.
2. GANZ, T. 2003. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783-788.
3. FINCH, C.A., K. DEUBELBEISS, J.D. COOK, et al. 1970. Ferrokinetics in man. Medicine (Baltimore) 49: 17-53.
4. HERSHKO, C., G. GRAHAM, G.W. BATES & E.A. RACHMILEWITZ. 1978. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 40: 255-263.
5. ANUWATANAKULCHAI, M., P. POOTRAKUL, P. THUVASETHAKUL & P. WASI. 1984. Non-transferrin plasma iron in β-thalassaemia/HbE and haemoglobin H diseases. Scand. J. Haematol. 32: 153-158.
6. PORTER, J.B., R.D. ABEYSINGHE, L. MARSHALL, et al. 1996. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88: 705-713.
7. LINK, G., A. PINSON & C. HERSHKO. 1985. Heart cells in culture: a model of myocardial iron overload and chelation. J. Lab. Clin. Med. 106: 147-153.
8. LINK, G., P. ATHIAS, A. GRYNBERG, et al. 1989. Effect of iron loading on transmembrane potential, contraction and automaticity of rat ventricular muscle cells in culture. J. Lab. Clin. Med. 113: 103-111.
9. BREUER, W., S. EPSZTEJN & Z.I. CABANTCHIK. 1997. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 382: 304-308.
10. HERSHKO, C. & D.J. WEATHERALL. 1988. Iron-chelating therapy. Crit. Rev. Clin. Lab. Sci. 26: 303-345.
11. BORGNA-PIGNATTI, C., S. RUGOLOTTO, P. DE STEFANO, et al. 1988. Survival and disease complications in thalassemia major. Ann. N.Y. Acad. Sci. 850: 227-231.
12. CAIRO, G., E. RAPPOCCIOLO, L. TACCHINI & L. SCHIAFFONATI. 1991. Expression of the genes for the ferritin H and L subunits in rat liver and heart. Evidence for tissue-specific regulations at pre- and post-translational levels. Biochem. J. 275: 813-816.
13. LINK, G., A. SAADA, A. PINSON, et al. 1998. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J. Lab. Clin. Med. 131: 466-474.
14. LINK, G., A. PINSON & C. HERSHKO. 1994. The ability of orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 83: 2692-2697.
15. MOREB, J., C. HERSHKO & Y. HASIN. 1988. Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells. Basic Res. Cardiol. 83: 360-368.
16. DAVIS, B.A., C. O'SULLIVAN, P.H. JARRITT, et al. 2004. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104: 263-269.
17. DAVIS, B.A. & J.B. PORTER. 2000. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95: 1229-1236.
18. MISKIN, H., I. YANIV, M. BERANT, et al. 2003. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation Eur. J. Haematol. 70: 398-403.
19. MODELL, B., M. KHAN & M. DARLISON. 2000. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355: 2051-2052.
20. CUNNINGHAM, M.J., E.A. MACKLIN & E.J. NEUFELD. 2004. Complications of β-thalassemia major in North America. Blood 104: 34-39.
21. GRADY, R.W., V.A. BERDOUKAS, E.A. RACHMILEWITZ, et al. 1999. Iron chelation therapy, a better approach. The 7th International Conference on Thalassaemia and the Haemoglobinopathies. Bangkok, Thailand, May-June 1999. Abstr. 0018.
22. BARMAN BALFOUR, J.A. & R.H. FOSTER. 1999. Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases. Drugs 58: 553-578.
23. HOFFBRAND, A.V., A. COHEN & C. HERSHKO. 2003. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102: 17-24.
24. MAGGIO, A., G. D'AMICO, A. MORABITO, et al. 2002. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol. Dis. 28: 196-208.
25. PIGA, A., C. GAGLIOTI, E. FOGLIACCO, et al. 2003. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88: 489-496.
26. ANDERSON, L.J., B. WONKE, E. PRESCOTT, et al. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360: 516-520.
27. PORTER, J.B., R.D. ABEYSINGHE, K.P. HOYES, et al. 1993. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyrid-4-one, CP94, relates to different metabolism of the iron chelating site. Br. J. Haematol. 85: 159-168.
28. HOYES, K.P. & J.B. PORTER. 1993. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br. J. Haematol. 85: 393-400.
29. HERSHKO, C., G. LINK, A. PINSON, et al. 1991. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood 77: 2049-2053.
30. AL-REFAIE, F.N., L.N. SHEPPARD, P. NORTEY, et al. 1995. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload Br. J. Haematol. 89: 403-407.
31. RICHARDSON, D.R. & P. PONKA. 1998. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. 131: 306-314.
32. GALANELLO, R., A. PIGA, D. ALBERTI, et al. 2003. Safety, tolerability and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron-overload due to beta-thalassemia. J. Clin. Pharmacol. 43: 565-572.
33. BERGERON, R.J., J. WIEGAND, J.S. MCMANIS, et al. 2002. Structure-activity relationships among desazadesferrithiocin analogues. Adv. Exp. Med. Biol. 509: 167-184.
34. BREUER, W., M.J. EMPERS, P. POOTRAKUL, et al. 2001. Deferoxamine- chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97: 792-798.
35. WONKE, B., C. WRIGHT & A.V. HOFFBRAND. 1998. Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol. 103: 361-364.
36. GRADY, R.W. & P.J. GIARDINA. 1999. Oral iron chelation: a potential role for HBED in combination therapy. American Society of Hematology, 41st Annual Meeting. December 1999. Blood 94(Suppl. 1): Abstr. 3293.
37. CECI, A., P. BAIARDI, M. FELISI, et al. 2002. The safety and effectiveness of deferiprone in a large-scale 3-year study in Italian patients. Br. J. Haematol. 118: 330-336.
38. HOFFBRAND, A.V., F. AL-REFAIE, B. DAVIS, et al. 1998. Long-term trial of deferiprone in transfusion-dependent iron overloaded patients. Blood 91: 295-300.